Ergoteles’s Nuvation Bio NUVB Stock Holding History

Ergoteles’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,299	Closed	-$45.3K	–	1354
2023 Q1	$45.3K	Sell	27,299 -119,830	-81%	-$243K	﹤0.01%	1141
2022 Q4	$282K	Buy	+147,129	New	+$298K	0.01%	933
2022 Q3	–	Sell	-510,003	Closed	-$1.65M	–	1845
2022 Q2	$1.65M	Buy	+510,003	New	+$2.22M	0.05%	362

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Ergoteles's NUVB Position: Q2 2023 in Review

Ergoteles sold out of Nuvation Bio (NUVB) in Q2 2023, closing a stake of 27,299 shares — an estimated $45.3K sold.

Ergoteles first reported a position in NUVB in Q2 2022 and held it in 3 quarters. The position peaked at $1.65M in Q2 2022. 124 funds tracked by Wall St. Rank hold NUVB as of Q2 2023.

Ergoteles reported no remaining Nuvation Bio position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 27,299 Nuvation Bio shares in Q2 2023, an estimated $45.3K.
Ergoteles first reported a position in Nuvation Bio in Q2 2022 and held it in 3 quarters.
Ergoteles's Nuvation Bio position peaked at $1.65M in Q2 2022.
124 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.